AstraZeneca has recently launched a new global health technology business, Evinova, with the goal of streamlining clinical trials and making them more accessible to patients. The company recognized a need for these services and decided to fill it by creating Evinova.
Evinova will operate as a separate business, but will be financially supported by AstraZeneca. The company will provide global services to CROs and pharmaceutical companies to design, conduct and monitor clinical trials. Evinova will charge users for access to its technology and will operate on a revenue-based model.
The creation of Evinova is aimed at addressing challenges and inefficiencies in the clinical trial process, ultimately making it easier for patients to participate and improving overall trial efficiency. This new venture reflects AstraZeneca’s commitment to advancing healthcare and using technology to improve the drug development process.